L735,524 - THE RATIONAL DESIGN OF A POTENT AND ORALLY BIOAVAILABLE HIV PROTEASE INHIBITOR

被引：0
|
作者：
DORSEY, BD
LEVIN, RB
MCDANIEL, SL
VACCA, JP
DARKE, PL
ZUGAY, JA
EMINI, EA
SCHLEIF, WA
QUINTERO, JC
LIN, JH
CHEN, IW
OSTOVIC, D
FITZGERALD, PMD
HOLLOWAY, MK
ANDERSON, PS
HUFF, JR
机构：
[1] MERCK SHARP & DOHME LTD,DEPT MED CHEM,W POINT,PA 19486
[2] MERCK SHARP & DOHME LTD,DEPT MOLEC BIOL,W POINT,PA 19486
[3] MERCK SHARP & DOHME LTD,DEPT VIRUS & CELL BIOL,W POINT,PA 19486
[4] MERCK SHARP & DOHME LTD,DEPT DRUG METAB,W POINT,PA 19486
[5] MERCK SHARP & DOHME LTD,DEPT PHARMACEUT RES,W POINT,PA 19486
[6] MERCK SHARP & DOHME LTD,DEPT BIOPHYS CHEM,W POINT,PA 19486
[7] MERCK SHARP & DOHME LTD,DEPT MOLEC SYST,W POINT,PA 19486
来源：
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY | 1993年 / 206卷
关键词：
D O I：
暂无
中图分类号：
O6 [化学];
学科分类号：
0703 ;
摘要：
引用
收藏
页码：6 / MEDI
相关论文
共 50 条
  • [41] Preclinical investigation of orally bioavailable, potent KRASMulti inhibitor JAB-23425
    Wang, Peng
    Wang, Yanping
    Sun, Xin
    Liu, Dan
    Liu, Xiaoyu
    Zhang, Wei
    He, Xueting
    Zhou, Rui
    Ma, Cunbo
    Li, Amin
    Lin, Yiwei
    Long, Wei
    CANCER RESEARCH, 2023, 83 (07)
  • [42] Discovery of a Potent and Orally Bioavailable Cyclophilin Inhibitor Derived from the Sanglifehrin Macrocycle
    Mackman, Richard L.
    Steadman, Victoria A.
    Dean, David K.
    Jansa, Petr
    Poullennec, Karine G.
    Appleby, Todd
    Austin, Carol
    Blakemore, Caroline A.
    Cai, Ruby
    Cannizzaro, Carina
    Chin, Gregory
    Chiva, Jean-Yves C.
    Dunbar, Neil A.
    Fliri, Hans
    Highton, Adrian J.
    Hui, Hon
    Ji, Mingzhe
    Jin, Haolun
    Karki, Kapil
    Keats, Andrew J.
    Lazarides, Linos
    Lee, Yu-Jen
    Liclican, Albert
    Mish, Michael
    Murray, Bernard
    Pettit, Simon B.
    Pyun, Peter
    Sangi, Michael
    Santos, Rex
    Sanvoisin, Jonathan
    Schmitz, Uli
    Schrier, Adam
    Siegel, Dustin
    Sperandio, David
    Stepan, George
    Tian, Yang
    Watt, Gregory M.
    Yang, Hai
    Schultz, Brian E.
    JOURNAL OF MEDICINAL CHEMISTRY, 2018, 61 (21) : 9473 - 9499
  • [43] PROTEIN STRUCTURE-BASED DESIGN OF POTENT ORALLY BIOAVAILABLE, NONPEPTIDE INHIBITORS OF HUMAN-IMMUNODEFICIENCY-VIRUS PROTEASE
    REICH, SH
    MELNICK, M
    DAVIES, JF
    APPELT, K
    LEWIS, KK
    FUHRY, MA
    PINO, M
    TRIPPE, AJ
    NGUYEN, D
    DAWSON, H
    WU, BW
    MUSICK, L
    KOSA, M
    KAHIL, D
    WEBBER, S
    GEHLHAAR, DK
    ANDRADA, D
    SHETTY, B
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1995, 92 (08) : 3298 - 3302
  • [44] Design and evaluation of dihydroisoquinolines as potent and orally bioavailable human cytomegalovirus inhibitors
    Chan, L
    Stefanac, T
    Turcotte, N
    Hu, ZH
    Chen, YM
    Bédard, J
    May, S
    Jin, HL
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2000, 10 (13) : 1477 - 1480
  • [45] Tipranavir (PNU-140690): A potent, orally bioavailable nonpeptidic HIV protease inhibitor of the 5,6-dihydro-4-hydroxy-2-pyrone sulfonamide class
    Turner, SR
    Strohbach, JW
    Tommasi, RA
    Aristoff, PA
    Johnson, PD
    Skulnick, HI
    Dolak, LA
    Seest, EP
    Tomich, PK
    Bohanan, MJ
    Horng, MM
    Lynn, JC
    Chong, KT
    Hinshaw, RR
    Watenpaugh, KD
    Janakiraman, MN
    Thaisrivongs, S
    JOURNAL OF MEDICINAL CHEMISTRY, 1998, 41 (18) : 3467 - 3476
  • [46] Design, Synthesis, and Biological Evaluation of an Orally Bioavailable, Potent, and Selective ROCK2 Inhibitor for Psoriasis Treatment
    Huang, Yun
    Mao, Chu-Ru
    Lou, Yijie
    Zhan, Shuai
    Chen, Zhe
    Ding, Wanjing
    Ma, Zhongjun
    JOURNAL OF MEDICINAL CHEMISTRY, 2023, 66 (22) : 15205 - 15229
  • [47] Synthesis of potent and orally active HIV-protease inhibitors
    Capraro, HG
    Bold, G
    Fassler, A
    Cozens, R
    Klimkait, T
    Lazdins, J
    Poncioni, B
    Rosel, JL
    Stover, D
    Lang, M
    ARCHIV DER PHARMAZIE, 1996, 329 (06) : 273 - 278
  • [48] Design and discovery of MRTX0902, a potent, selective, and orally bioavailable SOS1 inhibitor.
    Ketcham, John M.
    Briere, David M.
    Burns, Aaron C.
    Christensen, James G.
    Gunn, Robin J.
    Haling, Jacob
    Ivetac, Anthony
    Khare, Shilpi
    Kuehler, Jon
    Kulyk, Svitlana
    Laguer, Jade
    Lawson, John D.
    Moya, Krystal
    Nguyen, Natalie
    Olson, Peter
    Rahbaek, Lisa
    Smith, Christopher R.
    Sudhakar, Niranjan
    Thomas, Nicole C.
    Vanderpool, Darin
    Wang, Xiaolun
    Marx, Matthew A.
    CANCER RESEARCH, 2022, 82 (12)
  • [49] CGP-53437, AN ORALLY BIOAVAILABLE INHIBITOR OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 PROTEASE WITH POTENT ANTIVIRAL ACTIVITY
    ALTERI, E
    BOLD, G
    COZENS, R
    FAESSLER, A
    KLIMKAIT, T
    LANG, M
    LAZDINS, J
    PONCIONI, B
    ROESEL, JL
    SCHNEIDER, P
    WALKER, M
    WOODSCOOK, K
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1993, 37 (10) : 2087 - 2092
  • [50] D-DOPA Is a Potent, Orally Bioavailable, Allosteric Inhibitor of Glutamate Carboxypeptidase II
    Gori, Sadakatali S.
    Thomas, Ajit G.
    Pal, Arindom
    Wiseman, Robyn
    Ferraris, Dana, V
    Gao, Run-Duo
    Wu, Ying
    Alt, Jesse
    Tsukamoto, Takashi
    Slusher, Barbara S.
    Rais, Rana
    PHARMACEUTICS, 2022, 14 (10)
12345